Literature DB >> 21259399

Development and validation of a liquid chromatography and ion spray tandem mass spectrometry method for the quantification of artesunate, artemether and their major metabolites dihydroartemisinin and dihydroartemisinin-glucuronide in sheep plasma.

Urs Duthaler1, Jennifer Keiser, Jörg Huwyler.   

Abstract

Recently, promising fasciocidal activities of artesunate and artemether were described in rats and sheep. Therefore, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to quantify artesunate, artemether and their metabolites dihydroartemisinin and dihydroartemisinin-glucuronide in sheep plasma. Protein precipitation with methanol was used for sample workup. Reversed-phase high-performance liquid chromatography (HPLC) was performed using an Atlantis C18 analytical column with a mobile phase gradient system of ammonium formate and acetonitrile. The analytes were detected by MS/MS using selected reaction monitoring (SRM) with electrospray ionisation in the positive mode (transition m/z 267.4 → 163.0). The analytical range for dihydroartemisinin, dihydroartemisinin-glucuronide and artesunate was 10-1000 ng/ml and for artemether 90-3000 ng/ml with a lower limit of quantification of 10 and 90 ng/ml, respectively. Inter- and intra-day accuracy and precision deviations were < 10%. Consistent relative recoveries (60-80%) were observed over the investigated calibration range for all analytes. All analytes were stable in the autosampler for at least 30 h (6 °C) and after three freeze and thaw cycles. The validation results demonstrated that the LC-MS/MS method is precise, accurate and selective and can be used for the determination of the artemisinins in sheep plasma. The method was applied successfully to determine the pharmacokinetic parameters of artesunate and its metabolites in plasma of intramuscularly treated sheep.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21259399     DOI: 10.1002/jms.1883

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  6 in total

1.  The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine.

Authors:  Meitong Zang; Fanping Zhu; Lixia Zhao; Aijuan Yang; Xinxiu Li; Huixiang Liu; Jie Xing
Journal:  Malar J       Date:  2014-12-04       Impact factor: 2.979

2.  LC-UV/MS quality analytics of paediatric artemether formulations.

Authors:  Kirsten Vandercruyssen; Matthias D'Hondt; Valentijn Vergote; Herwig Jansen; Christian Burvenich; Bart De Spiegeleer
Journal:  J Pharm Anal       Date:  2013-04-25

3.  A simple sensitive UFLC-MS/MS method for the simultaneous quantification of artesunate, dihydroartemisinin and quercetin in rat plasma and its application to pharmacokinetic studies.

Authors:  Nethravathi Puttappa; Karthik Yamjala; Narenderan S T; Suresh Kumar Raman; Gowthamarajan Kuppusamy; Basuvan Babu; P Ram Kumar
Journal:  RSC Adv       Date:  2019-12-17       Impact factor: 4.036

4.  An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat.

Authors:  Fanping Zhu; Fuying Du; Xinxiu Li; Jie Xing
Journal:  Malar J       Date:  2012-11-21       Impact factor: 2.979

5.  Development of a specific monoclonal antibody-based ELISA to measure the artemether content of antimalarial drugs.

Authors:  Suqin Guo; Yongliang Cui; Lishan He; Liang Zhang; Zhen Cao; Wei Zhang; Rui Zhang; Guiyu Tan; Baomin Wang; Liwang Cui
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

6.  Exogenous Iron Increases Fasciocidal Activity and Hepatocellular Toxicity of the Synthetic Endoperoxides OZ78 and MT04.

Authors:  Karin Brecht; Carla Kirchhofer; Jamal Bouitbir; Francesca Trapani; Jennifer Keiser; Stephan Krähenbühl
Journal:  Int J Mol Sci       Date:  2019-10-01       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.